OncoDaily· @oncodaily · X·· 13 小时前评分70
正文 · 机器翻译
肿瘤科医生讨论 NATALEE 试验
在 #ESMO2026 上公布的 #NATALEE 试验六年期结果显示，对于 HR+/HER2− 早期乳腺癌患者，采用辅助 ribociclib 联合内分泌治疗可带来总生存期获益，并持续改善无侵袭性疾病生存期。
https://oncodaily.com/science/natalee-esmo-26-615553
@KefahMokbel @SuyogCancer @emadshash @Timothee_MD @DrBarbiOnc @HundalJasmin @Aydah_AlAwadhi @DrSGraff @dr_yakupergun @kazuki_nozawa @sara_soliman7 @stolaney1 @Dr_Oncologista @DrHBurstein
49 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：OncoDaily · x.com